Petros Pharmaceuticals Inc (PTPI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Petros Pharmaceuticals Inc (PTPI) has a cash flow conversion efficiency ratio of 0.156x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.49 Million) by net assets ($-9.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Petros Pharmaceuticals Inc worth for the company's overall valuation and market capitalisation.
Petros Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Petros Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Petros Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Petros Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Petros Pharmaceuticals Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BOOSH PLANT-BASED BRANDS
F:77I
|
N/A |
|
Xtract Resources PLC
LSE:XTR
|
-0.023x |
|
Headlam Group
LSE:HEAD
|
-0.182x |
|
Titon Holdings Plc
LSE:TON
|
-0.023x |
|
Sensys Traffic AB
ST:SENS
|
0.184x |
|
TAURUS GOLD CORP.
F:W1N
|
N/A |
|
Safestay PLC
LSE:SSTY
|
0.030x |
|
OCA Acquisition Corp
NASDAQ:OCAXU
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Petros Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Petros Pharmaceuticals Inc from 2018 to 2024. View Petros Pharmaceuticals Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.47 Million | $-2.60 Million | 0.349x | +157.04% |
| 2023-12-31 | $12.48 Million | $-7.63 Million | -0.611x | +20.24% |
| 2022-12-31 | $16.70 Million | $-12.80 Million | -0.766x | -129.59% |
| 2021-12-31 | $35.54 Million | $-11.86 Million | -0.334x | +61.91% |
| 2020-12-31 | $17.47 Million | $-15.31 Million | -0.876x | -377.43% |
| 2019-12-31 | $8.02 Million | $2.53 Million | 0.316x | +106.62% |
| 2018-12-31 | $-1.68 Million | $8.02 Million | -4.771x | -- |
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.